Tolerability of gefitinib in patients receiving treatment in everyday clinical practice

@inproceedings{Zandwijk2003TolerabilityOG,
  title={Tolerability of gefitinib in patients receiving treatment in everyday clinical practice},
  author={Nico van Zandwijk},
  booktitle={British Journal of Cancer},
  year={2003}
}
Gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, has recently been approved in several countries for use in advanced or metastatic non-small-cell lung cancer (NSCLC). In contrast to chemotherapies, which are generally used at or near their maximum-tolerated dose (MTD), gefitinib is used at an optimal biological dose (250 mg day−1), which is substantially below its MTD, minimising the risk of adverse events without compromising efficacy. Tolerability… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2003
View 17 Excerpts
Highly Influenced

Clinical benefits in patients with advanced nonsmall-cell lung cancer treated with gefitinib (‘Iressa’, ZD1839) in the compassionate use program

PA Janne, S Gurubhagavatula, +5 authors BE Johnson
Lung Cancer 41(Suppl • 2003
View 1 Excerpt

Gefitinib ( ’ Iressa ’ , ZD 1839 ) monotherapy as a salvage regimen for previously treated advanced non - small -

J Park, Park B-B, +7 authors K Park
cell lung cancer ( NSCLC ) Lung Cancer • 2003
View 1 Excerpt

Gefitinib (‘Iressa’, ZD1839) as a last option for patients with recurrent non-smallcell lung cancer (NSCLC). Poster presented at the 10th WCLC

A Haringhuizen, HFR Vaessen, P Baas, N van Zandwijk
2003
View 2 Excerpts

Gefitinib (‘Iressa’, ZD1839) in advanced non-small-cell lung cancer patients after progression on chemotherapy

A López Martin, M Constenla, +7 authors H Cortés-Funes
Poster presented at the ASCO. Chicago, IL, USA May • 2003
View 1 Excerpt

Gefitinib (’Iressa’, ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small-cell lung cancer

J Park, B-B Park, +7 authors K Park
(NSCLC). Lung Cancer 41(Suppl • 2003
View 1 Excerpt

Gefitinib in elderly patients with progressive, pretreated, non-small-cell lung cancer: results from the Istituto Clinico Humanitas

H Soto Parra, R Cavina, +6 authors A Santoro
Poster presented at the 10th WCLC, • 2003
View 1 Excerpt

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2003
View 1 Excerpt

Similar Papers

Loading similar papers…